Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 4, Number 2, April 2011, pages 58-63

Clinical Significance of Isolated Peri-Appendiceal Lesions in Patients With Left Sided Ulcerative Colitis

Figure 1. Peri-appendiceal lesion. (A) Typical endoscopic appearance of periappendiceal inflammation, “cecal patch” with a sharply demarcated border (arrows), seen in a patient with left sided ulcerative colitis. (B) Normal endoscopic appearance of the cecum.

**Table 1.** Baseline Characteristics of Patients With and Without a Cecal Patch
	Patients With Extension (N = 33)	Patients Without Extension (N = 90)	Unadjusted Odds Ratio (95% CI)
Sex
Female	20 (60.6)	69 (76.7)	2.1 (0.9 - 5.0)
Male	13 (39.4)	21 (23.3)
Mean age at diagnosis	32.9	38.4	1.0 (1.0 - 1.0)
Mean ESR	32.2	20.5	1.0 (1.0 - 1.0)
Mean CRP	16.7	17.2	1.0 (1.0 - 1.0)
Initial Mayo endoscopic severity score
1	12 (36.4)	48 (55.8)	2.2 (1.0 - 5.1)
2 or more	21 (63.6)	38 (44.2)
Mean WBC	8,033.3	7,864.1	1.0 (1.0 - 1.0)
Mean platelets	319	298.4	1.0 (1.0 - 1.0)
Family history of UC	3 (9.1)	2 (2.2)	3.5 (0.6 - 22.5)
Initial antibiotic use	3 (9.4)	3 (3.6)	2.8 (0.5 - 14.6)
Initial mesalamine suppository use	10 (31.3)	17 (20.0)	1.8 (0.7 - 4.6)
Initial steroid suppository use	4 (12.5)	11 (12.9)	1.0 (0.3 - 3.3)
Initial mesalamine/sulfa use	25 (78.1)	70 (82.4)	0.8 (0.3 - 2.1)
Initial oral steroid use	16 (50.0)	32 (37.7)	1.7 (0.7 - 3.8)

Table 1. Baseline Characteristics of Patients With and Without a Cecal Patch

Patients With Extension (N = 33)

Patients Without Extension (N = 90)

Unadjusted Odds Ratio (95% CI)

number (percent)

Sex

Female

20 (60.6)

69 (76.7)

2.1 (0.9 - 5.0)

Male

13 (39.4)

21 (23.3)

Mean age at diagnosis

32.9

38.4

1.0 (1.0 - 1.0)

Mean ESR

32.2

20.5

1.0 (1.0 - 1.0)

Mean CRP

16.7

17.2

1.0 (1.0 - 1.0)

Initial Mayo endoscopic severity score

12 (36.4)

48 (55.8)

2.2 (1.0 - 5.1)

2 or more

21 (63.6)

38 (44.2)

Mean WBC

8,033.3

7,864.1

1.0 (1.0 - 1.0)

Mean platelets

319

298.4

1.0 (1.0 - 1.0)

Family history of UC

3 (9.1)

2 (2.2)

3.5 (0.6 - 22.5)

Initial antibiotic use

3 (9.4)

3 (3.6)

2.8 (0.5 - 14.6)

Initial mesalamine suppository use

10 (31.3)

17 (20.0)

1.8 (0.7 - 4.6)

Initial steroid suppository use

4 (12.5)

11 (12.9)

1.0 (0.3 - 3.3)

Initial mesalamine/sulfa use

25 (78.1)

70 (82.4)

0.8 (0.3 - 2.1)

Initial oral steroid use

16 (50.0)

32 (37.7)

1.7 (0.7 - 3.8)

**Table 2.** Covariates for Proximal Extension of Ulcerative Colitis
	Cecal Patch (N = 20)	Control (N = 40)	P-value
Family History	4 (20)	7 (17.5)	NS
Laboratory Data
Platelets	316.9	323.8	NS
WBC	4,535	4,440	NS
ESR	23.2	23.4	NS
C-reactive protein	15.5	12.0	NS
Initial Therapy
Antibiotics	3 (15)	12 (20)	NS
5-ASA suppository	11 (55)	22 (55)	NS
Steroid suppository	5 (25)	18 (45)	NS
Oral ASA product	15 (75)	35 (87.5)	NS
Oral steroids	5 (27.8)	22 (55.0)	0.056
Mayo Endoscopic Severity Score
0	2 (10.5)	6 (15.0)	NS
1	11 (57.9)	17 (42.5)	NS
2 - 4	6 (31.6)	17 (42.5)	NS
Initial Extent
Proctitis	11 (55)	11 (27.8)	0.049
Left-sided colitis	9 (45)	29 (72.5)	0.049
Age at Diagnosis	27.6	30.7	NS
Mean Follow Up Time (months)	63.3	71.4	NS

Table 2. Covariates for Proximal Extension of Ulcerative Colitis

Cecal Patch (N = 20)

Control (N = 40)

P-value

number (percent)

Family History

4 (20)

7 (17.5)

Laboratory Data

Platelets

316.9

323.8

WBC

4,535

4,440

ESR

23.2

23.4

C-reactive protein

15.5

12.0

Initial Therapy

Antibiotics

3 (15)

12 (20)

5-ASA suppository

11 (55)

22 (55)

Steroid suppository

5 (25)

18 (45)

Oral ASA product

15 (75)

35 (87.5)

Oral steroids

5 (27.8)

22 (55.0)

0.056

Mayo Endoscopic Severity Score

2 (10.5)

6 (15.0)

11 (57.9)

17 (42.5)

2 - 4

6 (31.6)

17 (42.5)

Initial Extent

Proctitis

11 (55)

11 (27.8)

0.049

Left-sided colitis

9 (45)

29 (72.5)

0.049

Age at Diagnosis

27.6

30.7

Mean Follow Up Time (months)

63.3

71.4